CEPHALOSPORINS - PowerPoint PPT Presentation

About This Presentation
Title:

CEPHALOSPORINS

Description:

Cefadroxil, cephalexin. Cefazolin. First-generation. Oral Agents. Parenteral ... include Cefazolin (parenteral) as well as cefadroxil and cephalexin (oral) ... – PowerPoint PPT presentation

Number of Views:5733
Avg rating:3.0/5.0
Slides: 106
Provided by: johndb
Learn more at: https://s2.smu.edu
Category:

less

Transcript and Presenter's Notes

Title: CEPHALOSPORINS


1
CEPHALOSPORINS
2
1. Introduction
  • Antibacterial agents which inhibit bacterial cell
    wall synthesis
  • Discovered from a fungal colony in Sardinian
    sewer water (1948)
  • Cephalosporin C identified in 1961

3
6. Mechanism of Action
  • The acetoxy group acts as a good leaving group
    and aids the mechanism

4
The Cephalosporins
Generation Parenteral Agents Oral Agents
First-generation Cefazolin Cefadroxil, cephalexin
Second-generation Cefotetan, cefoxitin, cefuroxime Cefaclor, cefprozil, cefuroxime axetil, loracarbef
Third-generation Cefotaxime, ceftazidime, ceftizoxime, ceftriaxone Cefdinir, cefditoren, cefpodoxime proxetil, ceftibuten, cefixime
Fourth-generation Cefepime
5
8. First Generation Cephalosporins
Cephalothin
  • First generation cephalosporin
  • More active than penicillin G vs. some Gram -ve
    bacteria
  • Less likely to cause allergic reactions
  • Useful vs. penicillinase producing strains of S.
    aureus
  • Not active vs. Pseudonomas aeruginosa
  • Poorly absorbed from GIT
  • Administered by injection
  • Metabolised to give a free 3-hydroxymethyl group
    (deacetylation)
  • Metabolite is less active

6
8. First Generation Cephalosporins
Cephalothin - drug metabolism
Less active OH is a poorer leaving group
  • Strategy
  • Replace the acetoxy group with a metabolically
    stable leaving group

7
8. First Generation Cephalosporins
Cephaloridine
  • The pyridine ring is stable to metabolism
  • The pyridine ring is a good leaving group
    (neutralisation of charge)
  • Exists as a zwitterion and is soluble in water
  • Poorly absorbed through the gut wall
  • Administered by injection

8
8. First Generation Cephalosporins
Cefalexin
  • The methyl group at position 3 is not a good
    leaving group
  • The methyl group is bad for activity but aids
    oral absorption - mechanism unknown
  • Cefalexin can be administered orally
  • A hydrophilic amino group at the a-carbon of the
    side chain helps to compensate for the loss of
    activity due to the methyl group

9
First Generation Cephalosporins
Cefazolin
Cefadroxil
Cefalexin
10
First Generation Cephalosporins include Cefazolin
(parenteral) as well as cefadroxil and cephalexin
(oral).
Gram-positive bacteria Streptococcus pyogenes, Some virdans streptococci, Some Staphylococcus aureus, Some Streptococcus pneumoniae
Gram-negative bacteria Some Eschericia coli, Some Klebsiella pneumoniae, Some Proteus mirabilis
11
9. Second Generation Cephalosporins
9.1 Cephamycins
Cephamycin C
  • Isolated from a culture of Streptomyces
    clavuligerus
  • First b-lactam to be isolated from a bacterial
    source
  • Modifications carried out on the 7-acylamino side
    chain

12
9. Second Generation Cephalosporins
9.1 Cephamycins
Cefoxitin
  • Broader spectrum of activity than most first
    generation cephalosporins
  • Greater resistance to b-lactamase enzymes
  • The 7-methoxy group may act as a steric shield
  • The urethane group is stable to metabolism
    compared to the ester
  • Introducing a methoxy group to the equivalent
    position of penicillins (position 6) eliminates
    activity.

13
9. Second Generation Cephalosporins 9.2
Oximinocephalosporins
Cefuroxime
  • Much greater stability against some b-lactamases
  • Resistant to esterases due to the urethane group
  • Wide spectrum of activity
  • Useful against organisms that have gained
    resistance to penicillin
  • Not active against P. aeruginosa
  • Used clinically against respiratory infections

14
  • Second generation
  • The second-generation cephalosporins have a
    greater Gram-negative spectrum while retaining
    some activity against Gram-positive cocci. They
    are also more resistant to beta-lactamase.
  • Cefaclor (Ceclor, Distaclor, Keflor, Raniclor)
  • Cefonicid (Monocid)
  • Cefprozil (cefproxil Cefzil)
  • Cefuroxime (Zinnat, Zinacef, Ceftin, Biofuroksym)
  • Cefuzonam

15
Forms of Cefuroxime (2nd generation
cephalosporin)
Cefuroxime (ZINACEF)
Cefuroxime axetil (CEFTIN)
16
The Second-generation cephalosporins include
Cefotetan, cefoxitin, and cefuroxime (all
parenteral) as well as Cefaclor, cefprozil,
cefuroxime axetil, and loracarbef (all oral).
Gram-positive bacteria True cephalosporins have activity equivalent to first-generation agents. Cefoxitin and cefotetan have little activity
Gram-negative bacteria Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Haemophilus influenzae, Neisseria spp.
Anaerobic bacteria Cefoxitin and cefotetan have moderate anaerobic activity.
17
10. Third Generation Cephalosporins
Oximinocephalosporins
  • Aminothiazole ring enhances penetration of
    cephalosporins across the outer membrane of Gram
    -ve bacteria
  • May also increase affinity for the
    transpeptidase enzyme
  • Good activity against Gram -ve bacteria
  • Variable activity against Gram ve cocci
  • Variable activity vs. P. aeruginosa
  • Lack activity vs MRSA
  • Generally reserved for troublesome infections

18
10. Third Generation Cephalosporins
Oximinocephalosporins
Ceftazidime
  • Injectable cephalosporin
  • Excellent activity vs. P. aeruginosa and other
    Gram -ve bacteria
  • Can cross the blood brain barrier
  • Used to treat meningitis

19
The Third-generation Cephalosporins include
Cefotaxime, ceftazidime, ceftizoxime, and
ceftriaxone (all parenteral) as well as Cefdinir,
cefditoren, cefpodoxime proxetil, ceftibuten, and
cefixime (all oral).
Gram-positive bacteria Streptococcus pyogenes, Viridans streptococci, Many Streptococcus pneumoniae, Modest activity against Staphylococcus aureus
Gram-negative bacteria Escherichia coli, Klebsiella pneumoniae, Proteus spp. Haemophilus influenzae, Neisseria spp. Some Enterobacteriaceae.
Anaerobic bacteria
Atypical bacteria
Spirochetes Borrelia burgorferi
20
11. Fourth Generation Cephalosporins
Oximinocephalosporins
  • Zwitterionic compounds
  • Enhanced ability to cross the outer membrane of
    Gram negative bacteria
  • Good affinity for the transpeptidase enzyme
  • Low affinity for some b-lactamases
  • Active vs. Gram ve cocci and a broad array of
    Gram -ve bacteria
  • Active vs. P. aeruginosa

21
Fourth Generation Cephalosporins include cefepime
(parenteral).
Gram-positive bacteria Streptococcus pyogenes, Viridans streptococci, Many Streptocossus pneumoniae. Modest activity against Staphylococcus aureus
Gram-negative bacteria Escherichia coli, Klebsiella pneumoniae, Proteus spp. Haemophilus influenzae, Neisseria spp. Many other Enterobacteriaceae, Pseudomonas aeruginosa.
Anaerobic bacteria
Atypical bacteria
22
Newer b-Lactam Antibiotics
Thienamycin (Merck 1976)(from Streptomyces
cattleya)
  • Potent and wide range of activity vs Gram ve and
    Gram -ve bacteria
  • Active vs. Pseudomonas aeruginosa
  • Low toxicity
  • High resistance to b-lactamases
  • Poor stability in solution (ten times less stable
    than Pen G)

23
Newer b-Lactam Antibiotics
Thienamycin analogues used in the clinic
24
The Carbapenems include Imipenem/cilstatin,
Meropenem, and Ertapenem (all parenteral)
Gram-positive bacteria Streptococcus pyogenes, Viridans group streptococci, Streptococcus pneumoniae, Modest activity against Staphylococcus aureus, Some enterococci, Listeria monocytogenes
Gram-negative bacteria Haemophilus influenzae, Neisseria spp., Enterobacteriaceae, Pseudomonas aeruginosa
Anaerobic bacteria Bacteroides fragilis, Most other anaerobes.
25
Newer b-Lactam Antibiotics
Clinically useful monobactam
  • Administered by intravenous injection
  • Can be used for patients with allergies to
    penicillins
  • and cephalosporins
  • No activity vs. Gram ve or anaerobic bacteria
  • Active vs. Gram -ve aerobic bacteria

26
The Monobactams include only Aztreonam, which is
parenteral
Gram-positive bacteria
Gram-negative bacteria Haemophilus influenzae, Neisseria spp. Most Enterobacteriaceae, Many Pseudomonas aeruginosa.
Anaerobic bacteria
Atypical bacteria
27
Vancomycin
Vancomycin is called a glycopeptide, meaning
that it is a cyclic peptide, with sugar residues
attached to it.
28
Vancomycin Mechanism of Action
  • Bacterial Cell Wall Synthesis (review)
  • http//student.ccbcmd.edu/courses/bio141/lecguide/
    unit2/control/ppgsynanim.html

Penicillin Mechanism of Action (review) http//stu
dent.ccbcmd.edu/courses/bio141/lecguide/unit2/cont
rol/penres.html
  • http//student.ccbcmd.edu/courses/bio141/lecguide/
    unit2/control/vanres.html

29
Mechanism of Action of Vancomycin
Vancomycin binds to the D-alanyl-D-alanine
dipeptide on the peptide side chain of newly
synthesized peptidoglycan subunits, preventing
them from being incorporated into the cell wall
by penicillin-binding proteins (PBPs). In many
vancomycin-resistant strains of enterococci, the
D-alanyl-D-alanine dipeptide is replaced with
D-alanyl-D-lactate, which is not recognized by
vancomycin. Thus, the peptidoglycan subunit is
appropriately incorporated into the cell wall.
30
Vancomycin Uses
  • Vancomycin is used to treat aerobic Gram
    bacteria, including MRSA and strains of
    penicillin-resistant Streptococcus pneumoniae
  • Vancomycin is administered intraveneously
  • Vancomycin can also be used to treat anearobic
    Gram bacteria, including Clostridium difficile
    (in the case of a GI infection, Vancomycin can be
    administered orally).
  • Vancomycin cannot be used to treat Gram
    bacteria, since the large size of the vancomycin
    molecule prohibits its passing of the outer
    membrane.

31
Vancomycin Resistance
  • Some Enterococci have developed resistance to
    vancomycin (Enterococcus faecium and Enterococcus
    faecalis).
  • These bacteria are called Vancomycin Resistant
    Enterococci (VRE)
  • The mechanism of resistance involves the
    transformation of the D-Ala-D-Ala linkage in the
    peptide side chain into D-Ala-D-Lac (i.e.
    replacement of the NH2 group by an OH group)
  • This terminal linkage is still recognized by the
    essential PBPs (so the cell wall can still be
    constructed), but is not recognized by vancomycin
    (thus resulting in resistance).

32
Antimicrobial Activity of Vancomycin
Gram-positive bacteria Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes. Viridans group streptococci, Streptococcus pneumoniae, Some enterococci.
Gram-negative bacteria
Anaerobic bacteria Clostridium spp. Other Gram-positive anaerobes.
Atypical bacteria
33
Daptomycin
  • Daptomycin is called a lipopeptide antibiotic
  • Approved for use in 2003
  • Lipid portion inserts into the bacterial
    cytoplasmic membrane where it forms an
    ion-conducting channel.
  • Marketed under the trade name Cubicin

34
Uses of Daptomycin
  • Daptomycin is active against many aerobic
    Gram-positive bacteria
  • Includes activity against MRSA,
    penicillin-resistant Streptococcus pneumoniae,
    and some vancomycin-resistant Enterococci (VRE)
  • Daptomycin is not active against Gram negative
    strains, since it cannot penetrate the outer
    membrane.
  • Primarily been used to treat skin and soft tissue
    infections
  • Poor activity in the lung.

35
Antimicrobial Activity of Daptomycin
Gram-positive bacteria Streptococcus pyogenes, Viridans group streptococci, Streptococcus pneumoniae, Staphylococci, Enterococci.
Gram-negative bacteria
Anaerobic bacteria Some Clostridium spp.
Atypical
36
Rifamycins
  • Rifampin is the oldest and most widely used of
    the rifamycins
  • Rifampin is also the most potent inducer of the
    cytochrome P450 system
  • Therefore, Rifabutin is favored over rifampin in
    individuals who are simultaneously being treated
    for tuberculosis and HIV infection, since it will
    not result in oxidation of the antiviral drugs
    the patient is taking
  • Rifaximin is a poorly absorbed rifamycin that is
    used for treatment of travelers diarrhea.

37
Mechanism of Action of Rifampin
  • Rifampin inhibits transcription by inactivating
    bacterial RNA polymerase
  • Resistance develops relatively easily, and can
    result from one of a number of single mutations
    in the baqcterial gene that encodes RNA
    polymerase.
  • Therefore, Rifampin is rarely used as monotherapy
    (i.e. not used as a single agent) but usually
    combined with other antibiotics

38
Uses of Rifampin
  • Used, in combination with other drugs, to treat
    Mycobacterium tuberculosis
  • Used to treat some Staphylococcal infections.

39
The Rifamycins include Rifampin, Rifabutin,
Rifapentine, and Rifaximin, all of which can be
administered orally. Rifampin can also be
administered parenterally.
Gram-positive bacteria Staphylococci
Gram-negative bacteria Haemophilus influenzae, Neisseria meningitidis
Anaerobic bacteria
Mycobacteria Mycobacterium tuberculosis, Mycobacterium avium complex, Mycobacteriumleprae.
40
Aminoglycosides
The structure of the aminoglycoside amikacin.
Features of aminoglycosides include amino sugars
bound by glycosidic linkages to a relatively
conserved six-membered ring that itself contains
amino group substituents.
41
Aminoglycoside Mechanism of Action
  • Aminoglycosides bind to the 30S subunit of the
    bacterial ribosome, thereby inhibiting bacterial
    protein synthesis (translation)
  • http//www.microbelibrary.org/microbelibrary/files
    /ccImages/Articleimages/kaiser/mechanisms/altribo_
    antibiot.html
  • http//www.microbelibrary.org/microbelibrary/files
    /ccImages/Articleimages/kaiser/mechanisms/altribo_
    antibiot.html

42
Uses of Aminoglycoside Antibiotics
  • Unlike vancomycin, the aminoglycosides have
    excellent activity against Gram aerobic
    bacteria
  • Their extensive positive charge enables them to
    bind to and penetrate the negatively charged
    outer membrane and get into the periplasm
  • They are further transported into the cytoplasm
    by a bacterial transport system.

43
Lipopolysaccharide is Part of the Outer Membrane
of Gram Negative Bacteria
44
(No Transcript)
45
(No Transcript)
46
  • Bacterial lipopolysaccharides are toxic to
    animals. When injected in small amounts LPS or
    endotoxin activates several host responses that
    lead to fever, inflammation and shock. Endotoxins
    may play a role in infection by any Gram-negative
    bacterium. The toxic component of endotoxin (LPS)
    is Lipid A. The O-specific polysaccharide may
    provide for adherence or resistance to
    phagocytosis, in the same manner as fimbriae and
    capsules. The O polysaccharide (also referred to
    as the O antigen) also accounts for multiple
    antigenic types (serotypes) among Gram-negative
    bacterial pathogens. Thus, E. coli O157 (the
    Jack-in-the-Box and Stock Pavillion E. coli) is
    157 of the different antigenic types of E. coli
    and may be identified on this basis.

47
  • Bacterial resistance to aminoglycosides occurs
    via one of three mechanisms that prevent the
    normal binding of the antibiotic to its ribosomal
    target
  • Efflux pumps prevent accumulation of the
    aminoglycoside in the cytosol of the bacterium.
  • Modification of the aminoglycoside prevents
    binding to the ribosome.
  • Mutations within the ribosome prevent
    aminoglycoside binding.

48
The Aminoglycosides include Streptomycin,
Gentamicin, Tobramycin, and Amikacin (all
parenteral), as well as Neomycin (oral).
Gram-positive bacteria Used synergistically against some Staphylococci, Streptococci, Enterococci, and Listeria monocytogenes
Gram-negative bacteria Haemophilus influenzae, Enterobacteiaceae, Pseudomonas aeruginosa
Anaerobic bacteria
Atypical bacteria
Mycobacteria Mycobacterium tuberculosis, Mycobacterium avium complex.
49
Macrolides and Ketolides
The structures of erythromycin and telithromycin
Circled substituents and distinguish
telithromycin from the macrolides. Substituent
allows telithromycin to bind to a second site on
the bacterial ribosome.
50
Mechanism of Action of Macrolide Antibiotics
  • Macrolides bind tightly to the 50S subunit of the
    bacterial ribosome, thus blocking the exit of the
    newly synthesized peptide
  • Thus, they are interfering with bacterial
    translation
  • http//www.microbelibrary.org/microbelibrary/files
    /ccImages/Articleimages/kaiser/mechanisms/altribo_
    antibiot.html
  • http//www.microbelibrary.org/microbelibrary/files
    /ccImages/Articleimages/kaiser/mechanisms/altribo_
    antibiot.html

51
Uses of Macrolide Antibiotics
  • Active against a broad range of bacteria
  • Effective against some stphylococci and
    streptococci, but not usually used for MRSA or
    penicillin-resistant streptococci
  • Most aerobic Gram- bacteria are resistant
  • Active against many atypical bacteria and some
    mycobacteria and spirochetes

52
The macrolide group consists of Erythromycin,
Clarithromycin, and Azithromycin (all oral, with
erythromycin and azithromycin also being
available parenterally).
Gram-positive bacteria Some Streptococcus pyogenes. Some viridans streptococci, Some Streptococcus pneumoniae. Some Staphylococcus aureus.
Gram-negative bacteria Neiseria spp. Some Haemophilus influenzae. Bordetella pertussis
Anaerobic bacteria
Atypical bacteria Chlamydia spp. Mycoplasma spp. Legionella pneumophila, Some Rickettsia spp.
Mycobacteria Mycobacterium avium complex, Mycobacterium leprae.
Spirochetes Treponema pallidum, Borrelia burgdorferi.
53
Uses of Telithromycin (a ketolide)
  • Telithromycin is approved for use against
    bacterial respiratory infections
  • Active against most strains of Streptococcus
    pneumoniae, including penicillin- and
    macrolide-resistant strains
  • Also active against more strains of Staphylococci
  • Only available in oral formulation

54
The related ketolide class consists of
Telithromycin (oral).
Gram-positive bacteria Streptococcus pyogenes, Streptococcus pneumoniae, Some Staphylococcus aureus
Gram-negative bacteria Some Haemophilus influenzae, Bordetella pertussis
Anaerobic bacteria
Atypical bacteria Chlamydia spp. Mycoplasma spp. Legionella pneumophila
55
The Tetracycline Antibiotics
The structure of tetracycline
56
Tetracycline Antibiotics
Tetracycline
Tigecycline
Doxycycline
57
Mechanism of Action of the Tetracycline
Antibiotics
  • The tetracyclines bind to the 30S subunit of the
    bacterial ribosome and prevent binding by tRNA
    molecules loaded with amino acids.
  • http//student.ccbcmd.edu/courses/bio141/lecguide/
    unit2/control/tetres.html

58
Uses of the Tetracycline Antibiotics
  • Main use is against atypical bacteria, including
    reckettsiae, chlamydiae, and mycoplasmas
  • Also active agains some aerobic Gram-positive
    pathogens and some aerobic Gram-negative bacteria

59
The Tetracycline Class of Antibiotics consists of
Doxycycline and Tigecycline (parenteral) as well
as Tetracycline, Doxycycline and Minocycline
(oral)
Gram-positive bacteria Some Streptococcus pneumoniae
Gram-negative bacteria Haemophilus influenzae, Neisseria meningitidis
Anaerobic bacteria Some Clostridia spp. Borrelia burgdorferi, Treponema pallidum
Atypical bacteria Rickettsia spp. Chlamydia spp.
60
Tigecycline
61
The antimicrobial activity of Tigecycline
(parenteral)
Gram-positive bacteria Streptococcus pyogenes. Viridans group streptococci, Streptococcus pneumoniae, Staphylococci, Enterococci, Listeria monocytogenes
Gram-negative bacteria Haemophilus influenzae, Neisseria spp. Enterobacteriaceae
Anaerobic bacteria Bacteroides fragilis, Many other anaerobes
Atypical bacteria Mycoplasma spp.
62
Chloramphenicol
63
Mechanism of Action of Chloroamphenicol
  • Binds to the 50S subunit of the bacterial
    ribosome, where it blocks binding of tRNA

64
Uses of Chloramphenicol
  • Severe toxicity limits utility
  • The most serious side effect of chloramphenicol
    treatment is aplastic anaemia (a condition where
    bone marrow does not produce sufficient new cells
    to replenish blood cells)
  • This effect is rare and is generally fatal there
    is no treatment and there is no way of predicting
    who may or may not get this side effect.
  • The effect usually occurs weeks or months after
    chloramphenicol treatment has been stopped.

65
Uses of Chloramphenicol
  • However, despite its toxicity, chloramphenicol
    has a wide spectrum of activity, that includes
    many aerobic Gram-positive, Gram-negative,
    anaerobic, and atypical bacteria

66
The Antimicrobial Activity of Chloramphenicol
Gram-positive bacteria Streptococcus pyogenes, Viridans group streptococci. Some Streptococcus pneumoniae
Gram-negative bacteria Haemophilus influenzae, Neisseria spp. Salmonella spp. Shigella spp.
Anaerobic bacteria Bacteroides fragilis. Some Clostridia spp. Other anaerobic Gram-positive and Gram negative bacteria
Atypical bacteria Rickettsia spp. Chlamydia trachomatis, Mycoplasma spp.
67
Clindamycin
68
Mechanism of Action of Clindamycin
  • Clindamycin binds to the 50S subunit of the
    ribosome to inhibit protein synthesis

69
Uses of Clindamycin
  • Clindamycin is a member of the lincosamide series
    of antibiotics
  • Main utility is in treatment of Gram-positive
    bacteria and anaerobic bacteria
  • Active against staphylococcus, including some
    strains of MRSA
  • Not useful against Gram-negative bacteria

70
Toxicity of Clindamycin
  • Clindamycin kills many components of the
    gastrointestinalo flora, leaving only Clostridium
    difficile
  • This can result in overgrowth by C. difficile,
    which is resistant

71
The Antimicrobial Activity of Clindamycin (both
oral and parenteral)
Gram-positive bacteria Some Streptococcus pyogenes, Some viridans group streptococci. Some Streptococcus pneumoniae, Some Staphylococcus aureus
Gram-negative bacteria
Anaerobic bacteria Some Bacteroides fragilis, Some Clostridium spp. Most other anaerobes.
Atypical bacteria
72
Streptogramins
73
Mechanism of Action of Streptogramins
  • Dalfopristin inhibits the early phase of protein
    synthesis in the bacterial ribosome and
    quinupristin inhibits the late phase of protein
    synthesis. The combination of the two components
    acts synergistically and is more effective in
    vitro than each component alone.

74
Uses of the Streptogramins
  • Have activity against Gram positive aerobic
    bacteria
  • Including MRSA, penicillin-resistant
    Streptococcus pneumoniae and some VRE (active
    against vancomycin resistant Enterococcus
    faecelis, but not Enterococcus faecium)
  • The Quinupristin/Dalfopristin mixture is marketed
    as Synercid

75
The Antimicrobial Activity of Quinupristin/Dalfopr
istin (parenteral)
Gram-positive bacteria Streptococcus pyogenes, Viridans group streptococci, Streptococcus pneumoniae, Staphylococcus aureus, Some enterococci.
Gram-negative bacteria
Anaerobic bacteria
Atypical bacteria
76
The Oxazolidinones
The structure of Linezolide
77
Mechanism of Action of the Oxazolidinones
  • Binds to the 50S subunit and prevents association
    of this unit with the 30S subunit.
  • http//student.ccbcmd.edu/courses/bio141/lecguide/
    unit6/genetics/protsyn/translation/oxazolres_anim.
    html

78
Uses of the Oxazolidinones
  • Has excellent activity against most aerobic
    Gram-positive bacteria, including MRSA and VRE.
  • Only oxazolidonone on the market now is
    Linezolid, which is both oral and intravenous.

79
The Antimicrobial Activity of Linezolid (both
oral and parenteral)
Gram-positive bacteria Streptococcus pyogenes. Viridans group streptococci, Streptococcus pneumoniae, Staphylococci, Enterococci.
Gram-negative bacteria
Anaerobic bacteria
Atypical bacteria
80
The Sulfa Drugs
  • Most commonly used sulfa drug is a mixture of the
    sulfa drug Sulfamethoxazole and Trimethoprim
  • These two drugs work in synergy, with the
    combination being superior to either drug alone.
  • This combination is known as co-trimoxazole,
    TMP-sulfa, or TMP-SMX

Sulfamethoxazole
Trimethoprim
81
Mechanism of Activity of Sulfa Drugs
  • Trimethoprim-sulfamethoxazole works by preventing
    the synthesis of tetrahydrofolate (THF), an
    essential cofactor for the metabolic pathways
    that generate deoxynucleotides, the building
    blocks of DNA.

82
Tetrahydrofolic Acid Biosynthetic Pathway
  • In the first step of the pathway, the
    sulfonamides are mistaken for the natural
    substrate, p-aminobenzoic acid (PABA) and the
    drug acts as a competitive inhibitor of this
    enzyme
  • In a later step, the trimethoprim acts as a
    structural analog of dihydrofolate and therefore
    inhibits dihydrofolate reductase

83
Structural Resemblance of Sulfamethoxazole and
p-Aminobenzoic Acid
Sulfamethoxazole
p-Aminobenzoic Acid
84
Another sulfa drug is Dapsone, which is used to
treat Mycobacterium leprae
Dapsone
85
Structural Comparison of Two Sulfa Drugs
86
The Antimicrobial Activity of the Sulfa Drugs
Gram-positive bacteria Some Sreptococcus pneumoniae, Some Staphylococci, Listeria monocytogenes
Gram-negative bacteria Some Haemophilus influenzae, Some Enterobacteriaceae
Anaerobic bacteria
Atypical bacteria
Mycobacteria (Dapsone) Mycobacterium leprae
87
The Fluoroquinolones
88
Mechanism of Action Quinolones
  • Quinolone antibiotics inhibit bacterial DNA
    gyrase (Gram negative bacteria) or Topoisomerase
    IV (Gram positive bacteria)
  • http//can-r.ca/images/Flash/fluoroquinolones.swf

89
Uses of the Quinolone Antibiotics
  • Urinary Tract Infections fluoroquinolones are
    more effective than trimethoprim-sulfamethoxazole
  • Prostatitis
  • Respiratory tract infections
  • Gastrointestinal and Abdominal Infections

90
Antimicrobial Activity of the Quinolones (oral)
Gram-positive bacteria Some Staphylococcus aureus, Streptococcus pyogenes, Virdans group streptococci, Streptococcus pneumoniae
Gram-negative bacteria Neisseria spp. Haemophilus influenzae Many Enterobacteriaceae, Some Pseudomonas aeruginosa
Anaerobic bacteria Some clostridia spp, Some Bacteroides spp.
Atypical bacteria Chlamydia and Chlamydophilia, Mycoplasma pneumoniae, Legionella spp
Mycobacteria Mycobacterium tuberculosis, Mycobacterium avium complex, Mycobacterium leprae
91
Metronidazole (Flagyl)
Metronidazole is used in the treatment of
infections caused by anaerobic bacteria
92
Metronidazole Mechanism of Action
Metronidazole is a prodrug. It is converted in
anaerobic organisms by the redox enzyme
pyruvate-ferredoxin oxidoreductase. The nitro
group of metronidazole is chemically reduced by
ferredoxin (or a ferredoxin-linked metabolic
process) and the products are responsible for
disrupting the DNA helical structure, thus
inhibiting nucleic acid synthesis.
93
Mechanism of Action of Metronidazole
  • Metronidazole is selectively taken up by
    anaerobic bacteria and sensitive protozoal
    organisms because of the ability of these
    organisms to reduce metronidazole to its active
    form intracellularly.

94
  • Systemic metronidazole is indicated for the
    treatment of
  • Vaginitis due to Trichomonas vaginalis
    (protozoal) infection in both symptomatic
    patients as well as their asymptomatic sexual
    contacts
  • Pelvic inflammatory disease in conjunction with
    other antibiotics such as ofloxacin,
    levofloxacin, or ceftriaxone
  • Protozoal infections due to Entamoeba histolytica
    (Amoebic dysentery or Hepatic abscesses), and
    Giardia lamblia (Giardiasis) should be treated
    alone or in conjunction with iodoquinol or
    diloxanide furoate
  • Anaerobic bacterial infections such as
    Bacteroides fragilis, spp, Fusobacterium spp,
    Clostridium spp, Peptostreptococcus spp,
    Prevotella spp, or any other anaerobes in
    intraabdominal abscess, peritonitis, empyema,
    pneumonia, aspiration pneumonia, lung abscess,
    diabetic foot ulcer, meningitis and brain
    abscess, bone and joint infections, septicemia,
    endometritis, tubo-ovarian abscess, or
    endocarditis
  • Pseudomembranous colitis due to Clostridium
    difficile
  • Helicobacter pylori eradication therapy, as part
    of a multi-drug regimen in peptic ulcer disease
  • Prophylaxis for those undergoing potentially
    contaminated colorectal surgery and may be
    combined with neomycin

95
Antimicrobial Activity of Metronidazole (both
oral and intravenous)
Gram-positive bacteria
Gram-negative bacteria
Anaerobic bacteria Bacteroides fragilis, Clostridium spp. Most other anaerobes
Atypical bacteria
96
Antimicobacterial Agents
  • Mycobacterial infections are very slow
    progressing
  • Many antibiotics have poor activity against slow
    growing infections
  • Mycobacteria must be treated for a long time, and
    therefore, may readily develop resistance to a
    single antibiotic
  • Typically, several antibiotic agents are used
    simultaneously

97
Antimycobacterial Agents
Pyrazinamide
Rifampin
Ethambutol
98
Mycobacterial Infections
http//www.nature.com/nrmicro/animation/imp_animat
ion/index.html http//web.uct.ac.za/depts/mmi/lst
eyn/cellwall.html
99
Mycolic Acids provide protection
  • Mycolic acids are long fatty acids found in the
    cell walls of the mycolata taxon, a group of
    bacteria that includes Mycobacterium
    tuberculosis, the causative agent of the disease
    tuberculosis. They form the major component of
    the cell wall of mycolata species.
  • The presence of mycolic acids gives M.
    tuberculosis many characteristics that defy
    medical treatment. They lend the organism
    increased resistance to chemical damage and
    dehydration, and prevent the effective activity
    of hydrophobic antibiotics. In addition, the
    mycolic acids allow the bacterium to grow readily
    inside macrophages, effectively hiding it from
    the host's immune system.

100
(No Transcript)
101
Mechanism of Action of Anti-Mycobacterial
Antibiotics
  • Rifampin is an inhibitor of RNA polymerase
  • Isoniazide inhibits the synthesis of mycolic acid
  • Pyrazinoic acid inhibits the enzyme fatty acid
    synthetase I, which is required by the bacterium
    to synthesise fatty acids.
  • Ethambutol disrupts the formation of the cell wall

102
(No Transcript)
103
(No Transcript)
104
(No Transcript)
105
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com